Emerging Visual And Refractive Outcomes Of Smile Using The New Visumax 800 Laser

Published 2022 - 40th Congress of the ESCRS

Reference: FPM03.01 | Type: Free paper | DOI: 10.82333/h5rt-zh84

Authors: Amir Hamid* ¹ , Alex Shortt ¹ , Nabila Jones ² , Irene Sisó-Fuertes ² , Clare ODonnell ²

¹Eye Sciences,Optegra Eye Health Care,London,United Kingdom, ²Eye Sciences,Optegra Eye Health Care,Manchester,United Kingdom

Purpose

To report emerging clinical outcomes including complications, post-operative visual acuity, and refractive outcome data for SMILE using the new Visumax 800 femtosecond laser platform.

Setting

Optegra Eye Hospital London

Methods

A retrospective audit of clinical outcomes of consecutive patients following SMILE undertaken with the new Visumax 800 (Zeiss, Germany) for the correction of myopia/myopic astigmatism between November 2021 and February 2022 was conducted. Data audited were recorded in the Medisoft electronic medical record. Procedures were excluded from the analysis if they were enhancement procedures or amblyopic cases.

Results

Results from 179 eyes, 90 patients (45 female and 45 male) with Pre-op Spherical Equivalent (D) range +0.13 DS to -8.88DS were included. Mean age of patients was 33 ± 6 years. Postoperatively 98% of eyes achieved 20/40 and 78% of eyes achieved 20/20 (UDVA) or better. 84% of eyes had a SEQ within ±0.50D of predicted target. One operative complication “cap tear” was reported, (with no impact on visual outcome, UDVA 20/20). Six eyes were reported as postoperative dry eyes, four eyes had raised IOP >21mmhg and one patient had postoperative epithelial ingrowth (all maintained UDVA better than 20/40).

Conclusions

Our data show that SMILE procedures with the Visumax 800 had low operative and post operative complication rates and that early post operative visual and refractive outcomes were of an excellent standard. The Visumax 800 provided a safe and efficacious mode of corneal laser vision correction.